Brief: Minovia Therapeutics Receives FDA Fast Track Designation For MNV-201 In Myelodysplastic Syndrome
18/09/2025 12:45
Sept 18 (Reuters) - Minovia Therapeutics: MINOVIA THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR MNV-201 IN MYELODYSPLASTIC SYNDROME Source text: ID:nGNX662k3c ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Launch One Acquisition
See all newsBrief: Minovia Therapeutics Receives FDA Fast Track Designation For Mnv-201 In Myelodysplastic Syndrome
Brief: Minovia Therapeutics Receives FDA Fast Track Designation For MNV-201 In Myelodysplastic Syndrome
Brief: Minovia Therapeutics And Launch One Acquisition Announce JV To Create Mitochondrial Therapy Company
Brief: Launch One Acquisition Completes $230.0 Million Initial Public Offering